AGEN Class Action Notice: Robbins LLP Reminds Agenus Inc. Stockholders of Pending AGEN Class Action Lawsuit

Core Viewpoint - A class action has been filed against Agenus Inc. for allegedly misleading investors regarding the effectiveness and prospects of its drug candidates, particularly botensilimab and balstilimab, during the specified class period [1][2]. Group 1: Company Overview - Agenus Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology products, including balstilimab, an anti-PD-1 antagonist, and botensilimab, a CTLA-4 blocking antibody [1]. - The company is currently conducting Phase 2 clinical trials for both drug candidates, targeting second line cervical cancer and pancreatic cancer/melanoma, respectively [1]. Group 2: Allegations and Legal Action - The allegations state that Agenus failed to disclose that the combination therapy of botensilimab and balstilimab was less effective than claimed, leading to overstated clinical results and regulatory prospects [2]. - Following a press release on July 18, 2024, regarding the FDA's feedback on the drug combination, Agenus's stock price dropped by $10.43 per share, or 58.83%, closing at $7.30 per share [3]. Group 3: Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must submit their applications by November 5, 2024, although participation is not required to be eligible for recovery [4].